免疫疗法以外的新型疗法.pdf

1、Novel Therapies Outside Immunotherapy in RCCThai H.Ho,MD,PhDAssociate ProfessorBlatt-Ness Endowed Oncology ChairHollings Cancer Center Medical University of South CarolinaDisclosuresAdvisory board/consulting from Breakthrough Scientific,Cardinal Health,Exelixis,Ipsen,GlaxoSmithKline,Johnson and John

2、son,Merck,Neomorph,Novartis,Taiho Oncology.Royalties/patents from Champions Oncology,licensing of QSOX1 small molecule inhibitors,licensing of QSOX1 monoclonal antibodies,licensing of Galectin antibodies,licensing of Treg screening methods.EXCLUSION ZONE Doesnt respond to traditional cytotoxic chemo

3、therapy and has intra-tumoral heterogeneity Low incidence of traditional driver mutations(KRAS,TP53);high incidence of chromatin remodeling mutations which may facilitate metabolic reprogramming of the tumor and cross-talk with the microenvironment-mab(monoclonal antibodies)-tinib(tyrosine kinase in

4、hibitors)-tifan(HIF-2 inhibitors)-limus(mTOR inhibitors)Created in https:/BioR;US Adopted Names(USAN),WHO INNKidney cancer doesnt follow a traditional cancer playbookBelzutifan+Cabozantinib Combination in 1LLITESPARK-003 Cohort 1(IO nave)EXCLUSION ZONEORRPFSOSIpilimumab+nivolumab(P3-CM214)4012.452.7

5、Axitinib+pembrolizumab(P3-KN426)6115.747.2Cabozantinib+nivolumab(P3-CM9ER)5616.446.5Lenvatinib+pembrolizumab(P3-CLEAR)7123.953.7Belzutifan 120 mg+cabozantinib 60 mg(P2-Choueiri T Lancet Oncol.2025,N=50)7030.3NRChoueiri TK,Bauer RM et al.Lancet Oncol.Jan 2025.Zanzalintinib+Immunotherapy Combination i

6、n 1LSTELLAR-002EXCLUSION ZONEORRPFSOSIpilimumab+nivolumab(P3-CM214)4012.452.7Axitinib+pembrolizumab(P3-KN426)6115.747.2Cabozantinib+nivolumab(P3-CM9ER)5616.446.5Lenvatinib+pembrolizumab(P3-CLEAR)7123.953.7Belzutifan+cabozantinib7030.3NRZanzalintinib+nivolumab(Chahoud J.ASCO 2025,N=38)6318.5-Zanzalin